Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
2(22%)
Results Posted
200%(4 trials)
Terminated
3(33%)

Phase Distribution

Ph phase_2
5
56%
Ph phase_1
4
44%

Phase Distribution

4

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
5(55.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

2 of 6 finished

Non-Completion Rate

66.7%

4 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(2)
Terminated(4)
Other(1)

Detailed Status

Terminated3
Completed2
Active, not recruiting2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
40.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (44.4%)
Phase 25 (55.6%)

Trials by Status

completed222%
active_not_recruiting222%
terminated333%
unknown111%
withdrawn111%

Recent Activity

2 active trials
Showing 5 of 9
active_not_recruitingphase_2

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

NCT02717156
terminatedphase_2

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

NCT03146871
completedphase_2

sEphB4-HSA in Treating Patients With Kaposi Sarcoma

NCT02799485
active_not_recruitingphase_1

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

NCT02495896
completedphase_2

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

NCT03049618
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02717156Phase 2

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

Active Not Recruiting
NCT03146871Phase 2

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Terminated
NCT02799485Phase 2

sEphB4-HSA in Treating Patients With Kaposi Sarcoma

Completed
NCT02495896Phase 1

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Active Not Recruiting
NCT03049618Phase 2

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Completed
NCT03552796Phase 1

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Withdrawn
NCT04033432Phase 2

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Unknown
NCT03519984Phase 1

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

Terminated
NCT02767921Phase 1

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

Terminated

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9